Combining PARP and SIK2 inhibitors enhances cancer cell sensitivity to treatment.
A nonaqueous liquid fill matrix dissolves arsenic trioxide to eliminate dust hazards during manufacturing and prevent accidental exposure.
Tipifarnib treats squamous cell carcinoma by targeting tumors with high H-Ras expression, resolving variable patient response rates.
A nitrite-reductase promoter increases nitric oxide concentration in stored blood products through allosteric hemoglobin modulation.
Coated edible plant microvesicles deliver therapeutic agents to inflammatory sites using leukocyte plasma membranes.
Dichloroacetate primes leukemia cells to enhance arsenic trioxide potency, resolving the contradiction between therapeutic efficacy and treatment tolerability.
Intrapleural disulfiram delivery bypasses rapid blood metabolism to maintain therapeutic concentrations at the tumor site.
A genomic instability score quantifies chromosomal rearrangements to identify homologous recombination deficiency in tumor samples.
Local intratympanic injection prevents cisplatin-induced hearing loss without compromising antitumor activity.
Piezoelectric conversion of ultrasonic signals powers electrode pairs to generate cisplatin locally, eliminating systemic drug toxicity.
A hydrogen-enriched water generator uses a magnetic field to deliver ultra-long electromagnetic waves for electrolyzing regular water.
Manganese dioxide nanoparticle encapsulated in lipid and polymer layers delivers targeted therapy.
Combining acylfulvene with PARP inhibitors enhances cancer cell cytotoxicity through synergistic mechanisms.
Sodium, potassium, and magnesium sulfate salts stimulate intestinal motility to reduce transit time and ensure complete visualization during capsule endoscopy.
Optimized R1 and R2 molecular parameters in gold complexes achieve high selectivity against cervical, osteosarcoma, and colon cancers while reducing toxicity.
A computational model predicts optimal cisplatin injection sites and dosages within lung tumors based on tissue density.
Combining an FGFR inhibitor with conventional antitumor agents mitigates toxicity while sustaining tumor growth delay.
Complexing quercetin with phospholipids overcomes poor bioavailability, creating a synergistic immune-enhancing effect with beta glucan.
Carbon monoxide administration mediates cellular response to genotoxic stress, improving DNA repair efficiency while mitigating radiation-induced damage.
Analyzing plasma nitrite, exhaled nitric oxide, and genetic mutations to predict iNO therapy response and avoid unnecessary treatment.
A single conductivity sensor measures dialysis solution changes to determine bicarbonate and sodium concentrations.
Distinct polymorphic forms of compound A enhance aqueous solubility and stability to treat mTORC1-related disorders.
Coversin inhibits complement C5 and leukotriene B4, reducing side effects while improving treatment efficacy for rheumatoid arthritis.
A dietary supplement combining sodium bicarbonate, potassium citrate, and magnesium citrate increases urinary citrate levels.
Diarsenic tetraoxide dissolves rapidly in gastric juices to deliver arsenic ions, replacing IV infusions and reducing hospital stays.
Merging STAT3 inhibition with immune checkpoint blockade overcomes PDAC microenvironment suppression.
A wound insert uses biocompatible polymers to encapsulate reactive agents, delivering antimicrobial ions directly to the treatment site.
A composite nutraceutical formulation combining vitamins and phytochemicals to act as an immune booster and antimicrobial agent.
Self-assembling PEGylated phospholipid micelles encapsulate antigenic polypeptides to form stable nanocarriers.
A branched glycan therapeutic composition modulates gastrointestinal microbiota abundance through specific alpha-1,2-glycosidic bond configurations.